Innoviva, Inc. (INVA)
| Market Cap | 1.53B +28.9% |
| Revenue (ttm) | 440.00M +18.8% |
| Net Income | 357.24M +824.3% |
| EPS | 4.31 +708.3% |
| Shares Out | 72.25M |
| PE Ratio | 4.92 |
| Forward PE | 10.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,100,216 |
| Open | 21.11 |
| Previous Close | 21.11 |
| Day's Range | 21.06 - 21.45 |
| 52-Week Range | 16.52 - 25.15 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 35.00 (+65.02%) |
| Est. Earnings | Nov 4, 2026 |
About INVA
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ... [Read more]
Financial Performance
In 2025, Innoviva's revenue was $411.33 million, an increase of 14.67% compared to the previous year's $358.71 million. Earnings were $271.17 million, an increase of 1059.22%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for INVA stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 65.02% from the latest price.
News
Innoviva assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Innoviva (INVA) with an Outperform rating and $35 price target The market is valuing Innoviva as declining respiratory royalty company while assigning limited credit to...
Innoviva Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company has evolved into a diversified healthcare business with strong royalty cash flows, a rapidly growing specialty therapeutics platform, and innovative strategic investments. Non-royalty revenue now exceeds legacy royalties, and the portfolio includes five approved products and high-potential assets like Armata and Nortiva Bio.
Innoviva Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Specialty therapeutics revenue exceeded $200 million, driven by XACDURO and GIAPREZA, with strong U.S. and ex-U.S. growth. Nortiva's LYNX platform targets once-monthly oral contraceptives, supported by the Gates Foundation, and broad drug reformulation potential. Royalty streams remain resilient, funding ongoing investments and share repurchases.
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva management to meet virtually with Cantor Fitzgerald
Virtual Meeting to be held on August 19 hosted by Cantor Fitzgerald.
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO...
Innoviva price target lowered to $34 from $36 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Innoviva (INVA) to $34 from $36 and keeps an Overweight rating on the shares.
Innoviva reports Q2 EPS ($1.14), consensus 49c
Reports Q2 revenue $119.6M, consensus $110.98M. “Innoviva (INVA) delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial mo...
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva Quarterly report: Q2 2026
Innoviva has published its Q2 2026 quarterly earnings report on August 5, 2026.
Innoviva Earnings release: Q2 2026
Innoviva released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Innoviva’s Nortiva Bio launches to develop long-acting oral medicines
Nortiva Bio “announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX(TM) drug delivery platform. Nortiva’s LYNX...
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its p...
Innoviva announces distribution, licensing agreement with Dr. Reddy’s
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories (RDY) for the devel...
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreem...
Innoviva Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The business operates on three pillars: durable royalties, a rapidly growing specialty therapeutics platform, and a portfolio of high-potential healthcare assets. IST is driving strong growth with key products and new launches, while strategic investments and disciplined capital allocation support long-term value creation.
Innoviva management to meet with BTIG
Biotech Analyst Harrison holds a Meeting with Management in San Francisco on May 18 hosted by BTIG.
Innoviva management to meet with BTIG
Biotech Analyst Harrison holds a Meeting with Management in Texas on May 20 hosted by BTIG.
Innoviva price target raised to $42 from $35 at BTIG
BTIG raised the firm’s price target on Innoviva (INVA) to $42 from $35 and keeps a Buy rating on the shares after its Q1 results. Royalty revenue from Breo and…
Innoviva reports Q1 EPS $2.22 vs (74c) last year
Reports Q1 revenue $98M, consensus $101.56M. “We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful val...
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva Earnings release: Q1 2026
Innoviva released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Innoviva Quarterly report: Q1 2026
Innoviva has published its Q1 2026 quarterly earnings report on May 6, 2026.
Innoviva Proxy statement: Proxy filing
Innoviva filed a proxy statement on March 24, 2026, providing details for shareholder voting and corporate governance matters.
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of...